Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis
Journal article published in 2018 by
This paper was not found in any repository, but could be made available legally by the author.
Preprint: archiving allowed
Data provided by